GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MAIA Biotechnology Inc (AMEX:MAIA) » Definitions » Gross-Profit-to-Asset %

MAIA (MAIA Biotechnology) Gross-Profit-to-Asset % : 0.00% (As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is MAIA Biotechnology Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. MAIA Biotechnology's annualized Gross Profit for the quarter that ended in Jun. 2024 was $0.00 Mil. MAIA Biotechnology's average Total Assets over the quarter that ended in Jun. 2024 was $10.37 Mil. Therefore, MAIA Biotechnology's annualized Gross-Profit-to-Asset % for the quarter that ended in Jun. 2024 was 0.00%.

MAIA Biotechnology Gross-Profit-to-Asset % Historical Data

The historical data trend for MAIA Biotechnology's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MAIA Biotechnology Gross-Profit-to-Asset % Chart

MAIA Biotechnology Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Gross-Profit-to-Asset %
- - - -

MAIA Biotechnology Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of MAIA Biotechnology's Gross-Profit-to-Asset %

For the Biotechnology subindustry, MAIA Biotechnology's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MAIA Biotechnology's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MAIA Biotechnology's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where MAIA Biotechnology's Gross-Profit-to-Asset % falls into.


MAIA Biotechnology Gross-Profit-to-Asset % Calculation

MAIA Biotechnology's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=0/( (12.022+7.567)/ 2 )
=0/9.7945
=0.00 %

MAIA Biotechnology's annualized Gross-Profit-to-Asset % for the quarter that ended in Jun. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Jun. 2024 )/( (Total Assets (Q: Mar. 2024 )+Total Assets (Q: Jun. 2024 ))/ count )
=0/( (8.716+12.02)/ 2 )
=0/10.368
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Jun. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

MAIA Biotechnology Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of MAIA Biotechnology's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

MAIA Biotechnology Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MAIA Biotechnology Inc (AMEX:MAIA) » Definitions » Gross-Profit-to-Asset %
Comparable Companies
LTRN PTN CRIS SIOX SEEL LUMO UBX SLS MTEM CADL OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
444 West Lake Street, Suite 1700, Chicago, IL, USA, 06060
Website
https://www.maiabiotech.com
MAIA Biotechnology Inc is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of telomerase-positive cancer cells.
Executives
Ramiro Guerrero director 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Cristian Luput director 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Vlad Vitoc director, 10 percent owner, officer: Chief Executive Officer 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Joseph F Mcguire officer: Chief Financial Officer 6670 SPRINGLAKE ROAD, KEYSTONE HEIGHTS FL 32656
Stan Smith director 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Ngar Yee Louie director, 10 percent owner 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Jean-manasse Theagene director 500 PLACE D ARMES, SUITE 1800, MONTREAL A8 H2Y 2W2
Steven M Chaouki director C/O TRANSUNION, 555 WEST ADAMS STREET, CHICAGO IL 60661
Sergei Gryaznov officer: Chief Scientific Officer 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Laurentiu Vlad director 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Mihail Obrocea officer: Chief Medical Officer 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606